Browsing Tag

Partnering

580 posts

Pharma COVID Roundup: News from Moderna, AstraZeneca, Lilly, Roche
By

By
The latest on manufacturing, potential treatments, and testing for COVID-19 with news from Moderna, AstraZeneca, Lilly, Roche, Thermo Fisher, Inovio, Sinovac, and others. Manufacturing and supply of COVID-19 vaccines and…

Global Pharma Briefs: News from AstraZeneca, Takeda, Sanofi, BioNTech
By

By
A roundup of news from France (Sanofi), Germany (BioNTech), Japan (Takeda), the UK (AstraZeneca), and the US (Aurobindo). France Sanofi, Kiadis Pharma Update on $358-M AcquisitionSanofi and Kiadis Pharma, an…

Lilly in $812-M Supply Pact with US Gov’t for COVID-19 Drug
By

By
Eli Lilly and Company has entered into a $812.5-million purchase agreement with the US government for 650,000 additional doses of its neutralizing antibody against COVID-19, bamlanivimab (700 mg). The purchase…

Biogen, Sage Therapeutics in $3.1-Bn Pact for Certain Neurological Disorders
By

By
Biogen and Sage Therapeutics, a Cambridge, Massachusetts-based pharmaceutical company focused on central nervous system disorders, have entered into a global collaboration and license agreement to develop and commercialize therapies for…

Pharma COVID Roundup: News from J&J, Takeda, Amgen, Regeneron
By

By
The latest on manufacturing, potential treatments, and testing for COVID-19 with news from J&J, Takeda, Amgen, UCB, Regeneron, Novavax, Roche, Inovio, and Kaneka. Manufacturing and supply of COVID-19 vaccines and…

Global Pharma Briefs: News from CSL, Roche, GSK, AstraZeneca, BMS, Sanofi
By

By
A roundup of news from Australia (CSL’s Seqirus), China (Pfizer), The Netherlands (Roche), the UK (Eisai, GSK, AstraZeneca), and the US (BMS, Sanofi, Daiichi Sankyo, J&J). Australia Seqirus To Invest…

Novartis, Mesoblast in $1.35-Bn Deal for Cell Therapy
By

By
Novartis has formed an exclusive worldwide license and collaboration agreement, in a deal worth up to $1.355 billion ($50 million upfront and $1.305 billion in milestones and other payments), with…

Lilly, Precision BioSciences in $555-M Genome-Editing Deal
By

By
Eli Lilly and Company and Precision BioSciences, a Durham, North Carolina-based genome-editing company, have formed a research collaboration and exclusive license agreement to develop potential therapies for genetic disorders, in a…

Pharma COVID Roundup: News from Bausch, Inovio, and the FDA
By

By
The latest on manufacturing and potential treatments for COVID-19 with news from Bausch Health, Inovio, the FDA, Bharat Biotech, and the Medicines Patent Pool. Manufacturing and supply of COVID-19 vaccines…

Pfizer, BioNTech To Submit EUA Request to FDA for COVID-19 Vaccine
By

By
Pfizer and BioNTech, a Mainz, Germany-based immunotherapy company, have achieved the safety data milestone required by the US Food and Drug Administration (FDA) for submission of emergency use authorization (EUA)…